There are currently no approved treatments in Canada that can slow the progression of Alzheimer's, only drugs to quiet ...

The benefit-risk balance is tipping more in favor of Eli Lilly’s Kisunla in early Alzheimer’s disease as the FDA ...

Because Alzheimer’s is just one of several diseases that cause dementia, the key distinction lies in their scope.

The FDA approved a label update with a new titration schedule for donanemab (Kisunla), an anti-amyloid drug approved to treat ...

Eli Lilly and Company (LLY) announced on Wednesday that the U.S. Food and Drug Administration (FDA) has approved a label ...

As Alzheimer's disease progresses beyond the early stages, the behavior changes and emotional impacts of the disease can be ...

The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of ...

A commonly prescribed pain medication—gabapentin—often considered a safer alternative to opioids for those who suffer from low back pain is now under scrutiny after being linked to increased risks of ...

INmune Bio said on Monday its experimental Alzheimer's drug failed to improve cognitive functions in patients with early ...

A research team from Virginia Commonwealth University has found that a drug currently in clinical trials for brain disorders ...

Quest will offer the first FDA-approved blood test to help detect Alzheimer’s-related amyloid pathology in patients with ...

After decades of setbacks, Alzheimer’s drug development is expanding beyond anti-amyloids, with a record number of trials and ...